Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in Swedish children and adolescents with ADHD
2004-003941-42Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Atomoxetine + psychoeducation with Placebo + psychoeducation (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2004; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2004-003941-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003941-42.